Form 4: Artiva CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Artiva Biotherapeutics' President and CEO, Fred Aslan, sold 3,187 shares of common stock at $6 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Fred Aslan, President and CEO, and a Director of Artiva Biotherapeutics, Inc. (ARTV), reported a transaction.
• The transaction involved the disposition of 3,187 shares of Artiva Biotherapeutics Common Stock.
• The shares were sold at a price of $6 per share.
• The transaction was executed on December 15, 2025.
• This sale was conducted pursuant to a Rule 10b5-1 Plan, which was adopted by Mr. Aslan on July 23, 2024.
• Following this transaction, Mr. Aslan directly beneficially owns 1,209,948 shares of Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine disclosure of an insider stock sale executed under a pre-arranged 10b5-1 plan, which is common for personal financial management and typically does not reflect a change in management's outlook on the company's prospects.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived as a minor negative signal, though its impact is mitigated by the pre-planned nature.

Future Outlook

NA

Industry Context

This is a routine insider transaction disclosure for a biotechnology company. Such transactions are common for executives managing personal finances and are typically not indicative of broader industry trends unless they are unusually large or frequent across multiple companies.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by a key executive, particularly under a 10b5-1 plan, is unlikely to have a significant direct impact on shareholder value or perception. It is generally viewed as a personal financial planning event rather than a signal of company performance.

Key Dates

Recommendation

The reported transaction is a routine insider sale of a relatively small number of shares by the CEO, executed under a pre-arranged 10b5-1 trading plan. Such sales are typically for personal financial planning and do not inherently signal a change in the company's fundamental outlook or warrant a shift in investment strategy. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an existing investment thesis.

Keywords

Artiva Biotherapeutics, ARTV, Fred Aslan, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, CEO